Vendor, South San Francisco, CA, part of Roche Holding AG
Genentech Inc.
UEI F7F8GZXL7Q93, CAGE 1HZ12
2 awards and $69,390,394 obligated between March 13, 2024 and July 29, 2026, 100% under full and open competition, against 1.0 offers on average where reported. 9 of the awards trace back to a SAM.gov solicitation on this site.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | $68,304,864 |
| Food and Drug Administration | $1,085,530 |
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $69,390,394 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50118D00036March 13, 2024, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Supplemental Funding, Revise Ottr, and Revise Statement of Work.NAICS 541714, PSC AN13 | $68,304,864 |
| 75F40125C00069Definitive Contract, September 11, 2025, Full and Open Competition, 1 offersSolicitation | FDA Office of Acq Grant SVCSFood and Drug Administration | This Project Focuses on Addressing Critical Challenges in the Design and Analysis of Hybrid Randomized Controlled Trials (Rcts) in LongitudiNAICS 541714, PSC AJ11 | $1,085,530 |
- Places of performance
- Maryland
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental DevelopmentAJ11 General Science And Technology R&D Services; General Science And Technology; Basic Research
- Transactions
- 14 across 2 awards